Current and emerging treatment options in chronic myeloid leukemia

Elias Jabbour, Jorge E. Cortes, Francis J. Giles, Susan O'Brien, Hagop M. Kantarjian

Research output: Contribution to journalReview article

95 Scopus citations

Abstract

Treatments for chronic myeloid leukemia (CML) represent a success story in molecular medicine. The development of imatinib, a tyrosine kinase inhibitor (TKI) targeted against the causative Bcr-Abl oncoprotein in CML, has resulted in hematologic and cytogenetic remissions in all phases of CML. A significant proportion of patients are resistant to imatinib or develop resistance during treatment. This is often a result of mutated forms of the Bcr-Abl oncoprotein to which imatinib is unable to bind. Several strategies have been developed to overcome the problem of imatinib resistance, including high-dose imatinib, novel targeted agents, and combination treatments. Novel agents include dasatinib, a potent TKI that inhibits several critical oncogenic proteins and which has recently been approved for patients with CML who are resistant or intolerant to imatinib; and nilotinib, a potent selective Bcr-Abl kinase inhibitor currently in clinical development. Other agents in development include SKI-606 and INNO-406. Stem cell transplantation remains a useful option, although it is not generally used as first-line treatment. Overall, there are an increasing number of treatment options available for patients with CML.

Original languageEnglish (US)
Pages (from-to)2171-2181
Number of pages11
JournalCancer
Volume109
Issue number11
DOIs
StatePublished - Jun 1 2007
Externally publishedYes

    Fingerprint

Keywords

  • Dasatinib
  • Imatinib
  • Leukemia
  • Myeloid
  • Philadelphia-positive

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Jabbour, E., Cortes, J. E., Giles, F. J., O'Brien, S., & Kantarjian, H. M. (2007). Current and emerging treatment options in chronic myeloid leukemia. Cancer, 109(11), 2171-2181. https://doi.org/10.1002/cncr.22661